Rezafungin acetate is a Synthetic peptide, Cyclic Peptide targeting 1,3-beta-glucan synthase, at Approved. This 2026 report reviews clinical evidence.

Clazakizumab is a Monoclonal antibody targeting IL-6, at Phase 2/3. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.

Roflumilast is a Small molecule drug targeting PDE4, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Ibrexafungerp Citrate is a Small molecule drug targeting 1,3-beta-glucan synthase, at Approved. This 2026 report reviews clinical evidence, IP, deals.

Mavacamten is a Small molecule drug targeting Cardiac myosin, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Sonelokimab is a Nanobody, Trispecific antibody targeting IL-17A x IL-17F x albumin, at Phase 3. This 2026 report reviews clinical evidence, IP, deals.

Acoramidis is a Small molecule drug targeting TTR, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Ivonescimab is a Bispecific antibody targeting PD-1 x VEGF-A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

A 2026 licensing due diligence report on Efimosfermin alfa, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.

A 2026 licensing due diligence report on LM-299, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.

A 2026 licensing due diligence report on BDTX-4933, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.

A 2026 licensing due diligence report on Felzartamab, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.